These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 18991661)

  • 1. Drugs used to treat Parkinson's disease, present status and future directions.
    Abdel-Salam OM
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U; Del Dotto P
    Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamate receptors as therapeutic targets for Parkinson's disease.
    Johnson KA; Conn PJ; Niswender CM
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological treatments of Parkinson's disease].
    Nomoto M; Iwata S; Kaseda S
    Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):111-22. PubMed ID: 11233302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in the pharmacological treatment of Parkinson's disease.
    Tuite P; Riss J
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
    Cacabelos R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Search for safer and potent natural inhibitors of Parkinson's disease.
    Khan ST; Ahmed S; Gul S; Khan A; Al-Harrasi A
    Neurochem Int; 2021 Oct; 149():105135. PubMed ID: 34271080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current Pharmacological Treatment for Parkinson's Disease].
    Saitoh Y; Takahashi K
    Brain Nerve; 2023 May; 75(5):441-449. PubMed ID: 37194511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
    Blandini F; Greenamyre JT
    Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 15. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
    Luthra PM; Kumar JB
    Mini Rev Med Chem; 2012 Dec; 12(14):1556-64. PubMed ID: 22697513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
    Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
    PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
    Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
    CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamate receptors and Parkinson's disease: opportunities for intervention.
    Marino MJ; Valenti O; Conn PJ
    Drugs Aging; 2003; 20(5):377-97. PubMed ID: 12696997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in development for Parkinson's disease.
    Johnston TH; Brotchie JM
    Curr Opin Investig Drugs; 2004 Jul; 5(7):720-6. PubMed ID: 15298067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.